CCRN · Endocrine, Hematology/Immunology, GI, Renal/GU, Integumentary · 8 min read · Open lesson
Diabetic Emergencies: DKA, HHS and Glucose Control
- Differentiate the underlying pathophysiology, laboratory findings, fluid deficits, and clinical presentations of diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS).
- Apply critical care nursing priorities for fluid resuscitation, electrolyte management, continuous insulin titration, and resolution criteria in hyperglycemic emergencies.
- Formulate immediate nursing actions for rapid identification and emergency management of hypoglycemia, including the use of IV dextrose and glucagon.
Pathophysiology and Clinical Differentiation: DKA Versus HHS
Diabetic ketoacidosis (DKA) stems from an absolute or profound relative deficiency of insulin coupled with an outpouring of counter-regulatory hormones, specifically glucagon, cortisol, catecholamines, and growth hormone. Insulin deficiency reduces glucose uptake by insulin-dependent tissues and increases hepatic glucose production; together with counter-regulatory hormones, it also promotes lipolysis and ketogenesis, producing ketonemia and metabolic acidosis. Blood glucose is typically elevated in DKA, but it may also be below 250 mg/dL in cases of euglycemic DKA. In contrast, hyperglycemic hyperosmolar state (HHS) occurs when endogenous insulin levels remain sufficient to suppress significant lipolysis and ketogenesis, yet are wholly insufficient to prevent severe hyperglycemia. Consequently, HHS presents with severe hyperglycemia, generally at least 600 mg/dL, and profound hyperosmolality without significant ketoacidosis.
The severe hyperglycemia in HHS drives an extreme osmotic diuresis, yielding an effective serum osmolality above 300 mOsm/kg or a total serum osmolality above 320 mOsm/kg. This severe hyperosmolality causes substantial cellular dehydration throughout the body. While a patient in DKA faces a typical fluid deficit of 3 to 6 liters, a patient experiencing HHS accumulates an immense fluid deficit of 8 to 10 liters. Furthermore, HHS carries a higher mortality rate than DKA, largely driven by older patient age, severe dehydration, and significant comorbid conditions. The extreme dehydration and hyperosmolality also drastically increase thromboembolic risk in HHS, making it essential for the critical care nurse to assess regularly for thrombosis and implement ordered venous thromboembolism prophylaxis when appropriate.
Clinical assessment reveals distinct presentations shaped by these different metabolic states, although DKA and HHS can occasionally overlap. Patients with DKA often demonstrate Kussmaul respirations, deep, rapid breaths acting as a respiratory compensatory mechanism to blow off carbon dioxide, along with acetone-scented breath, abdominal pain, nausea, and vomiting, particularly when acidosis is severe. These gastrointestinal and respiratory signs are generally absent in uncomplicated HHS. Instead, HHS can cause neurological dysfunction associated with hyperosmolality and cellular dehydration, with lethargy, confusion, seizures, and coma becoming more likely as osmolality rises. Because acute cerebral pathology can mimic these symptoms, any new or focal neurological findings warrant an immediate evaluation for other potential causes.
| Clinical Parameter | Diabetic Ketoacidosis (DKA) | Hyperglycemic Hyperosmolar State (HHS) |
|---|---|---|
| Primary Pathophysiology | Absolute or profound relative insulin deficiency with excess counter-regulatory hormones (glucagon, cortisol, catecholamines, growth hormone) | Endogenous insulin sufficient to suppress lipolysis/ketogenesis, but insufficient to control glucose |
| Diagnostic Hallmarks | Ketonemia, metabolic acidosis, and usually hyperglycemia (euglycemic DKA can occur) | Severe hyperglycemia, hyperosmolality, and profound dehydration without significant ketoacidosis |
| Typical Glucose Level | Usually elevated, but may be below 250 mg/dL | Generally at least 600 mg/dL (levels can overlap) |
| Osmolality & Fluid Deficit | Osmolality variable; typical fluid deficit of 3 to 6 liters | Effective osmolality > 300 mOsm/kg or total > 320 mOsm/kg; fluid deficit of 8 to 10 liters |
| Distinctive Clinical Signs | Kussmaul respirations, acetone breath, nausea, vomiting, abdominal pain | Lethargy, confusion, seizures, coma, high thromboembolic risk |
Hemodynamic Resuscitation and Fluid Selection
Initial intravenous fluid resuscitation for both DKA and HHS commonly uses an isotonic crystalloid, such as 0.9% sodium chloride or a balanced crystalloid, guided by provider orders and patient status. For adult patients without significant cardiac or renal compromise, the initial isotonic fluid replacement is commonly infused at about 500 to 1,000 mL/hr for the first 2 to 4 hours. The bedside nurse closely modulates these infusions based on clinical markers of tissue perfusion, ongoing fluid balance, and provider parameters. Think of this early stage as refilling a completely drained plumbing system before attempting fine pressure calibrations.
Following initial resuscitation, subsequent IV fluid selection and infusion rates depend upon hemodynamic trends, fluid balance, corrected sodium levels, osmolality trends, and baseline cardiac and renal function. Severe hyperglycemia draws water out of cells into the vascular space, artificially diluting serum sodium measurements. To estimate the sodium corrected for hyperglycemia, add approximately 1.6 mEq/L to the measured sodium value for each 100 mg/dL of blood glucose above 100 mg/dL, recognizing that a larger correction factor may be utilized in marked hyperglycemia. A low corrected sodium often supports continued isotonic crystalloid replacement, whereas a normal or elevated corrected sodium does not automatically require switching to 0.45% sodium chloride. Instead, the nurse must assess overall systemic perfusion alongside the trajectory of both sodium and osmolality when carrying out fluid orders.
As fluid resuscitation and insulin therapy drive blood glucose downward, fluid composition must be proactively altered to prevent adverse complications. In DKA, dextrose is generally added to IV fluids once blood glucose falls to approximately 200 to 250 mg/dL. This crucial step permits the continuous insulin infusion to run at rates sufficient to clear active ketoacidosis while guarding the patient against hypoglycemia. In HHS, where ketoacidosis is absent but cellular dehydration is extreme, dextrose is typically added to IV fluids once blood glucose reaches approximately 300 mg/dL.
Electrolyte Titration and Continuous Insulin Infusion Management
Before initiating an insulin infusion, potassium evaluation is an absolute clinical safety priority. Insulin shifts potassium out of the extracellular space and into the intracellular compartment by directly stimulating the sodium-potassium ATPase pump. Serum potassium levels frequently appear normal or elevated initially in DKA despite severe total-body potassium depletion; this paradox occurs because insulin deficiency, hyperosmolality, and acidemia collectively shift potassium out of cells prior to treatment. If measured serum potassium is below 3.5 mEq/L, the critical care nurse must withhold insulin, notify the provider immediately, and replace potassium per orders. Administering insulin in this setting can precipitate lethal hypokalemia and cardiac dysrhythmias.
When baseline or replacement serum potassium is between 3.5 and 5.0 mEq/L, anticipate potassium replacement, often ordered as 20 to 30 mEq per liter of IV maintenance fluid. Prior to infusing potassium, the nurse must verify renal function and confirm adequate urine output, generally seeking an output of at least 0.5 mL/kg/hr, while tracking serial potassium levels to prevent hyperkalemia. Meanwhile, continuous intravenous regular insulin serves as the standard formulation for treating DKA and HHS, titrated strictly according to protocol and provider orders. Monitor point-of-care blood glucose at the frequency specified by the IV insulin protocol, commonly every 1 to 2 hours during DKA or HHS treatment, and increase monitoring when glucose is changing rapidly or hypoglycemia is suspected.
During active therapy for DKA, a typical and safe rate of blood glucose decline is approximately 50 to 75 mg/dL per hour. If glucose fails to decline as expected within the first hour, the critical care nurse assesses hydration status, checks potassium levels, verifies infusion line delivery, follows the titration protocol, and notifies the provider as indicated. In HHS, rapid osmotic shifts must be meticulously avoided. Overshooting titration goals and allowing overly rapid declines in glucose and osmolality can provoke cerebral injury. The nurse must continuously track glucose, sodium, osmolality, and neurological checks, immediately reporting sudden headaches or neurological deterioration for evaluation of cerebral injury. Regarding acid-base balance, sodium bicarbonate is generally avoided in DKA; a provider may consider it only for severe acidemia (typically a pH below 7.0), during which the nurse must monitor closely for complications, especially worsening hypokalemia.
Anion Gap Closure, Resolution Criteria, and Subcutaneous Transition
In DKA, continuous IV insulin must be maintained alongside dextrose infusions until ketoacidosis is definitively resolved, rather than prematurely stopped when blood glucose reaches a normal target. Serum anion gap monitoring is a routine component of this evaluation, calculated using the standard formula: Sodium minus the sum of Chloride and Bicarbonate. Interpret the anion gap using the laboratory’s reference range; an elevated gap in DKA may reflect ketoacids but can also reflect other unmeasured anions, so it is not specific for ketonemia. However, anion gap closure alone is not a definitive resolution criterion, nor is it strictly required to establish that DKA has resolved.
Formal DKA resolution is generally indicated by a plasma beta-hydroxybutyrate level below 0.6 mmol/L paired with a venous pH of at least 7.3 or a serum bicarbonate of at least 18 mEq/L. In HHS, resolution requires a different set of targets: serum osmolality below 300 mOsm/kg, blood glucose below 250 mg/dL, adequate urine output, and demonstrable improvement in mental status toward baseline. Aligning with the AACN Synergy Model competencies of clinical judgment and caring practices, the critical care nurse synthesizes hemodynamic stability, fluid balance, and laboratory trends, communicating any signs of physiological deterioration promptly to the interprofessional team.
Once resolution criteria are met and the patient is ready to transition off the intravenous insulin infusion, careful timing is essential to prevent rebound metabolic decompensation. The nurse must ensure that ordered subcutaneous basal insulin overlaps the IV insulin infusion before discontinuation. This overlap must be maintained for at least 1 to 2 hours, and often 2 to 4 hours when long-acting subcutaneous formulations are administered. Abruptly stopping an intravenous insulin infusion without this subcutaneous basal bridge rapidly leaves the patient without circulating insulin, frequently triggering recurrent hyperglycemia and ketosis.
Acute Hypoglycemia: Recognition, Staging, and Rapid Intervention
Hypoglycemia is defined as a blood glucose below 70 mg/dL, with values below 54 mg/dL representing clinically significant hypoglycemia. Severe hypoglycemia is defined functionally: any episode characterized by altered physical or cognitive functioning that requires another person's assistance to resolve, regardless of the specific blood glucose value. The clinical manifestations of hypoglycemia divide into autonomic and neuroglycopenic signs. Autonomic warning signs, mediated by sympathetic nervous system activation, include diaphoresis, tachycardia, tremors, anxiety, and pallor. In contrast, neuroglycopenic signs reflect cellular starvation within the central nervous system, producing confusion, agitation, slurred speech, seizures, focal neurological deficits, and coma.
Crucially, patients receiving beta-adrenergic blocking agents may not exhibit classic autonomic signs such as tachycardia and tremors, as these medications blunt sympathetic responses. However, diaphoresis typically remains unaffected and serves as an important physical clue in these patients. Emergency management depends on patient acuity, cognitive status, and vascular access. For an awake, cooperative patient with mild hypoglycemia and an intact swallow reflex, 15 to 20 grams of fast-acting oral carbohydrates is the treatment of choice.
For an unconscious patient or an individual with severe hypoglycemia who possesses intravenous access, the nurse administers IV dextrose per established protocol, such as 10% dextrose or 25 g delivered as 50 mL of 50% dextrose in water (D50W), and immediately prepares to recheck glucose. Because intravenous 50% dextrose is a hypertonic vesicant, the nurse must ensure vascular access is fully patent before and during administration to avoid severe tissue irritation and extravasation injury. If IV access is unavailable, glucagon should be administered per protocol or orders, such as 1 mg intramuscularly or subcutaneously, or 3 mg intranasally where available, while vascular access is actively pursued. Note that glucagon acts primarily by mobilizing hepatic glycogen stores; it may prove ineffective in patients with depleted glycogen, such as those experiencing prolonged starvation or severe liver disease. Following any emergency intervention for hypoglycemia, bedside blood glucose must be rechecked within 15 minutes to confirm biochemical recovery.
Common mistakes
- Initiating an intravenous insulin infusion when serum potassium is below 3.5 mEq/L, which drives potassium into cells via the sodium-potassium ATPase pump and can precipitate fatal dysrhythmias.
- Discontinuing the continuous IV insulin infusion in DKA as soon as blood glucose reaches 200 to 250 mg/dL, rather than continuing insulin with added IV dextrose until ketoacidosis resolves.
- Stopping an IV insulin infusion without administering subcutaneous basal insulin 1 to 2 hours (or 2 to 4 hours for long-acting formulations) prior to discontinuation, causing rebound hyperglycemia and ketogenesis.
- Assuming beta-blockers conceal all signs of hypoglycemia, failing to recognize that diaphoresis typically remains unmasked even when tachycardia and tremors are suppressed.
Summary
- DKA involves insulin deficiency and counter-regulatory hormone excess leading to ketonemia, metabolic acidosis, and a 3 to 6 liter fluid deficit; HHS features severe hyperglycemia (glucose >= 600 mg/dL), hyperosmolality (> 300 mOsm/kg effective, > 320 mOsm/kg total), profound dehydration (8 to 10 liter deficit), and high thromboembolic risk.
- Initial resuscitation begins with isotonic crystalloids at 500 to 1,000 mL/hr for the first 2 to 4 hours in patients without cardiac/renal compromise; dextrose is added at 200 to 250 mg/dL in DKA and at approximately 300 mg/dL in HHS.
- Serum potassium must be at least 3.5 mEq/L before starting insulin; if potassium is under 3.5 mEq/L, withhold insulin, notify the provider, and replace potassium per orders.
- Target glucose reduction during insulin titration in DKA is 50 to 75 mg/dL/hr; avoid overly rapid drops in glucose and osmolality to reduce the risk of cerebral injury, and report any acute neurological changes immediately.
- DKA resolution requires plasma beta-hydroxybutyrate < 0.6 mmol/L and venous pH >= 7.3 or bicarbonate >= 18 mEq/L (anion gap closure alone is not definitive); subcutaneous basal insulin must overlap the IV infusion by 1 to 2 hours (2 to 4 hours for long-acting) before IV insulin discontinuation.
- Hypoglycemia (< 70 mg/dL, clinically significant < 54 mg/dL, or severe when assistance is required) is treated with 15 to 20 g fast-acting oral carbohydrates if awake, IV dextrose (e.g., vesicant D50W or 10% dextrose) if unconscious with access, or glucagon (IM/subQ/intranasal) if no IV access; recheck blood glucose within 15 minutes.
Practice this section
Explained CCRN Endocrine, Hematology/Immunology, GI, Renal/GU, Integumentary questions, no account needed. CCRN Endocrine, Hematology/Immunology, GI, Renal/GU, Integumentary practice test
5 practice questions and 20 flashcards for this lesson are in your tests.global account.
Log in to use themThis is an open sample lesson. The full CCRN study guide (58 lessons so far) is included with CCRN plans, together with the practice question bank.
- 1 month
$58.99$29.49 - 3 months
$173.99$86.99 - Lifetime
$350.99$175.49
One payment, no subscription.
See CCRN plansAlready a member? Log in
25 practice questions on this exam
Each CCRN practice test has 25 original questions with the answers explained. No account needed.
Open the CCRN practice testsOriginal lesson written for CCRN practice · updated October 31, 2026. Exam names are trademarks of their owners; tests.global is not affiliated with them.